Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
Clinics ; 68(6): 858-864, jun. 2013. tab, graf
Article Dans Anglais | LILACS | ID: lil-676929

Résumé

OBJECTIVES: Myeloid-derived suppressor cells contribute to the immunosuppressive microenvironment during tumor development and limit the efficacy of cancer immunotherapy. Identifying myeloid-derived suppressor cells and associated factors is the first step in creating strategies to reverse the suppressive effects of these cells on the immune system. METHODS: To induce lung cancer, we administered 2 doses of urethane to BALB/c mice and observed these animals for 120 days. After this period, we evaluated the percentage of myeloid-derived suppressor cells in the blood, lung and bone marrow. The expression of alpha-smooth muscle actin, transforming growth factor-β, Toll-like receptor 2, Toll-like receptor 4, and interleukin-6 was also determined in the lung tissue. RESULTS: Myeloid-derived suppressor cells were increased in all evaluated tissues after lung cancer development in association with increased Toll-like receptor 4 expression and decreased interleukin-6 expression in the lung. We observed alpha-smooth muscle actin and transforming growth factor-β expression in lung nodules. CONCLUSIONS: We believe that the early diagnosis of cancer through determining the blood levels of myeloid-derived suppressor cells followed by the depletion of these cells should be further investigated as a possible approach for cancer treatment. .


Sujets)
Animaux , Mâle , Souris , Tumeurs du poumon/anatomopathologie , Cellules myéloïdes/anatomopathologie , Actines/métabolisme , Technique de Western , Cancérogènes , Cytométrie en flux , Immunohistochimie , /métabolisme , Tumeurs du poumon/induit chimiquement , Tumeurs du poumon/immunologie , Poumon/effets des médicaments et des substances chimiques , Poumon/anatomopathologie , Souris de lignée BALB C , Cellules myéloïdes/immunologie , Facteurs temps , /métabolisme , Uréthane
2.
Yonsei Medical Journal ; : 928-930, 2003.
Article Dans Anglais | WPRIM | ID: wpr-205352

Résumé

This report documents a case of myeloid erythrophagocytosis in a patient with myeloproliferative disorder. The patient had pancytopenia and his marrow was hyperplastic with erythrophagocytosis by myeloid cells of various stages, including myeloblasts. He was diagnosed to have a prefibrotic stage of chronic idiopathic myelofibrosis. The erythrophagocytosis by myeloid cells persisted even after 2 months of treatment for the primary disorder.


Sujets)
Humains , Mâle , Adulte d'âge moyen , Érythrocytes/anatomopathologie , Cellules myéloïdes/anatomopathologie , Syndromes myéloprolifératifs/anatomopathologie , Pancytopénie/anatomopathologie , Phagocytose
SÉLECTION CITATIONS
Détails de la recherche